ISSN 1214-0287 (on-line)
ISSN 1214-021X (printed)

Volume 7 (2009), No 2, p 93-99

Is a high dose of Huperzine A really suitable for pretreatment against high doses of soman?

Jana Zdarova Karasova, Jiri Bajgar, Ladislav Novotny, Kamil Kuca

Address: Jana Zdarova Karasova, Faculty of Military Health Sciences, Department of Toxicology, Trebesska 1575, 500 01 Hradec Kralove, Czech Republic

Received 12th February 2009.
Revised 27th March 2009.
Published online 30th April.

Full text article (pdf)
Full text article (html)

Huperzine A (Hup A) is a reversible AChE inhibitor that crosses the blood-brain barrier. It is presently approved for, or is in a course of clinical trials for, the treatment of Alzheimer's disease. This compound has also been successfully tested for the pretreatment of organophosphate poisoning. Organophosphate nerve agents are potent irreversible inhibitors of acetylcholinesterase in the central and also in the peripheral compartment. In this study Hup A in a higher dose (500 micro g/kg) was tested as a prophylaxis against a high, mainly centrally acting, nerve agent (soman). According to the results obtained, Hup A in this dosage was not able to protect AChE against soman in both the peripheral and central compartments. The effect of Hup A and soman was found to be additive and all animal subjects died.

Huperzine A; soman; brain; nerve agent; acetylcholinesterase; pretreatment

Aldridge WN: Organophosphorus compounds and carbamates, and their reactions with esterases. Brit Med Bul 25:239-239, 1969.

Andersson RD, Harris LW, Woodard CL, Lennox WI: The effects of pyridostigmine pretreatment on oxime efficacy against intoxication by soman and VX in rats. Drug Chem Toxicol 15:285-294, 1992.

Ashani Y, Peggins J, Doctor BP: Mechanism of inhibition of cholinesterases by huperzine A Biochem Biophys Res Cummun 184:719-726, 1992.

Bajgar J, Fusek J, Patocka J, Hrdina V: Protective effect of 9-amino-7-methoxy-1,2,3,4-tetrahydroacridine against O-ethyl-S-(2-dimethylaminoethyl) methyl-phosphono-thiolate in vivo. Arch Toxicol 54:163-166, 1983.

Bajgar J: Organophosphates/nerve agent poisoning: mechanism of action, diagnosis, prophylaxis, and treatment. Adv Clin Chem 38:151-216, 2004.

Bajgar J, Fusek J, Kuca K, Bartosova L, Jun D: Treatment of organophosphate intoxication using cholinesterase reactivators: facts and fiction. Mini Rev Med Chem 7:461-466, 2007a.

Bajgar J, Hajek P, Karasova J, Slizova D, Krs O, Kuca K, Jun D, Fusek J, Capek L: Inhibition of acetylcholinesterase in different structures of the rat brain following soman intoxication pretreated with huperzine A Int J Mol Sci 8:1165-1175, 2007b.

Eckert S, Eyer P, Worek F: Reversible inhibition of acetylcholinesterase by carbamates or Huperzine A increases residual activity of the enzyme upon soman challenge. Toxicology 233:180-186, 2007.

Ellman GL, Coutney DK, Andres V, Featherstone RM: A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 7:88-95, 1961.

Filliant P, Foquin A, Lallement G: Effects of chronic administration of huperzine A on memory in guinea pigs. Drug Chem Toxicol 25:9-24, 2002.

Fusek J: Tacrin and its analogues, antidotes against psychotomimetics with anticholinergic effect. (in Czech) Voj Zdrav Listy 46:21-27, 1977.

Gunwald J, Raveh L, Doctor BP, Ashani Y: Huperzine A as a pretreatment candidate drug against nerve agent toxicity. Life Sci 54:991-997, 1994.

Holmstedt B: Pharmacology of organophosphorus cholinesterase inhibitors. Pharmacol Rev 11:567-688, 1959.

Cheng DH, Tang XC: Comparative studies of huperzine A, E2020, and tacrine on behavior and cholinesterase activities. Pharmacol Biochem Be 60:377-386, 1998.

Koelle GB: Protection of cholinesterase against irreversible inactivation by DFP in vitro. J Pharmacol Exp Therap 88:323-327, 1946.

Koster R: Synergisms and antagonisms between physostigmine and diisopropyl fluorophosphates in cats. J Pharmacol Exp Therap. 88:39-46, 1946.

Kubin L, Fenik V: Pontine cholinergic mechanisms and their impact on respiratory regulation. Physiol Neurobiol 143:235-249, 2004.

Lallement G, Veyret J, Masqueliez C, Aubriot S, Burckhart MF, Baubichon D: Efficacy of huperzine in preventing soman-induced seizures, neuropathological changes and lethality. Fundam Clin Pharmacol 11:387-394, 1997.

Lallement G, Demoncheaux JP, Foquin A, Baubichon D, Galonnier M, Clarençon D, Dorandeu F: Subchronic administration of pyridostigmine or huperzine to primates: compared efficacy against soman toxicity. Drug Chem Toxicol 25:309-320, 2002a.

Lallement G, Baille V, Baubichon D, Carpentier P, Collombet JM, Filliant P, Foquin A, Four E, Masquelies C, Testylier G, Tonduli L, Dorandeu F: Review of the value of huperzine as pretreatment of organophosphate poisoning. Neurotoxicology 23:1-5, 2002b.

Patocka J: Huperzine A - An interesting anticholinesterase compound from the Chinese herbal medicine. Acta Med (Hradec Kralove) 41:155-157, 1998.

Patocka J, Jun D, Bajgar J, Kuca K: Prophylaxis against nerve agent intoxications. Defence Sci J 56:775-784, 2006.

Tondulli LS, Testylier G, Masqueliez C, Lallement G, Monmaur P: Effects of huperzine used as pre-treatment against soman-induced seizures. Neurotoxicology 22:29-37, 2001.

Zangara A: The psychopharmacology of huperzine A: an alkaloid with cognitive enhancing and neuroprotective properties of interest in the treatment of Alzheimer's disease. Pharmacol Biochem Be 75:675-686, 2003.

Zhao Q, Tang XC: Effects of huperzine A on acetylcholinesterase isoforms in vitro: comparison with tacrine, donepezil, rivastigmine and physostigmine. Eur J Pharmacol 455:101-107, 2002.

Zdarova Karasova J Chladek J, Hroch M, Fusek J, Hnidkova D, Kuca K. Pharmacokinetic study of two acetylcholinesterase reactivators, trimedoxime and newly synthesized oxime K027, in rat plasma. J Appl Toxicol. 33: 18-23, 2013.

Bajgar J, Kassa J, Pohanka M, Zdarova Karasova J, Novotny L, Fusek J, Blaha V. Inhibition of blood and tissue cholinesterases by soman in guinea pigs in vivo. J Appl Biomed. 9: 35-41, 2011.

Soukup O, Holas O, Binder J, Killy K, Tobin G, Jun D, Fusek J, Kuca K. The effect of trimedoxime on acetylcholinesterase and on the cholinergic system of the rat bladder. J Appl Biomed. 8: 1-6, 2010.

Zdarova Karasova J, Stodulka P, Pohanka M, Kuca K. In vitro screening of blood-brain barrier penetration of monoquaternary acetylcholinesterase reactivators. Anal Lett. 43: 1516-1524, 2010.

Soukup O, Holas O, Binder J, Killy K, Tobin G, Jun D, Fusek J, Kuca K. The effect of trimedoxime on acetylcholinesterase and on the cholinergic system of the rat bladder. J Appl Biomed. 8: 87-92, 2010.

Musilova L, Jun D, Palecek J, Cirkva V, Musilek K, Paar M, Hrabinova M, Pohanka M, Kuca K. Novel nucleophilic compounds with oxime group as reactivators of paraoxon-inhibited cholinesterases. Lett Drug Des Discovery. 7: 260-264, 2010.

Zdarova Karasova J, Stodulka P, Kuca K. In vitro screening of blood-brain barrier penetration of clinically used acetylcholinesterase reactivators. J Appl Biomed. 8: 35-40, 2010.

Zdarova Karasova J, Novotny L, Antos K, Zivna H, Kuca K. Time-dependent changes in concentration of two clinically used acetylcholinesterase reactivators (HI-6 and obidoxime) in rat plasma determined by HPLC techniques after in vivo administration. Anal Sci. 26: 63-67, 2010.

Kuca K, Musilek K, Pohanka M, Dohnal V, Patocka J. Reactivation potency of the acetylcholinesterase reactivator obidoxime is limited. Biomed Papers. 153: 259-262, 2009.

Aracava Y, Pereira EFR, Akkerman M, Adler M, Albuquerque EX. Effectiveness of Donepezil, Rivastigmine, and (+/-)Huperzine A in Counteracting the Acute Toxicity of Organophosphorus Nerve Agents: Comparison with Galantamine. J Pharmacol Exp Ther. 331: 1014-1024, 2009.

Zdarova Karasova J, Bajgar J, Novotny L, Kuca K. Pretreatment with Huperzine A Protects Acetylcholinesterase in the Rat Brain Against Inhibition by VX and Russian VX. Lett Drug Des Discovery. 6: 563-567, 2009.

Zdarova Karasova J, Bajgar J, Jun D, Pavlikova, Kuca K. Time-Course Changes of Acetylcholinesterase Activity in Blood and Some Tissues in Rats After Intoxication by Russian VX. Neurotox Res. 16: 356-360, 2009.

Kuca K, Musilek K, Jun D, Pohanka M, Zdarova Karasova J, Novotny L, Musilova L. Could oxime HI-6 really be considered as "broad-spectrum" antidote? J Appl Biomed. 7: 143-149, 2009.

Gupta AK, Greenway FL, Cornelissen G, Pan W, Halberg F. Prediabetes is associated with abnormal circadian blood pressure variability. J Human Hypertens. 22: 627-633, 2008.

Cornelissen G, Halberg F, Otsuka K, Singh RB, Chen CH. Chronobiology predicts actual and proxy outcomes when dipping fails. Hypertension. 49: 237-239, 2007.